Navigation Links
FDA Stem Cell Approval Breakthrough Laudable
Date:1/23/2009

SAN CLEMENTE, Calif., Jan. 23 /PRNewswire/ -- Today the FDA announced approval for the first clinical trials on humans using Embryonic Stem Cells but Adult Stem Cell scientist Christian Drapeau says the experts may not be telling the whole story; Adult Stem Cells have greater potential with less risk.

"While the FDA approval is an exciting step forward toward freeing science from the shackles of politics," said Drapeau. "The expert commentary we're seeing surrounding the FDA's action is misleading."

Christian Drapeau, an early advocate of ASC science, posits that ACS are showing the greatest potential for scientific and medical advances.

Drapeau says that ASC can be a safer alternative to Embryonic Stem Cells because of a lower risk of tumor formation while studies show ASC to have comparable potential or even more in repairing damaged tissues or organs. This contradicts experts on morning talk shows who cast doubt on the efficacy of ACS research.

"The use of ASC requires a different thinking, but they can be as effective as ESC, if not more. ASC do not grow easily in vitro and they are not easy to re-program. But there are ways of using ASC that can be just as effective as methods using ESC, without the risk of tumor formation."

"Adult Stem Cells are showing great promise," notes Drapeau. "This is a very very important area of research right now and people must realize that Embryonic Stem Cells are not the only Stem Cell phenomenon out there."

"The scientific community is rejoicing today as a new age of medicine is ushered in concurrent with the Obama administration but the possibilities of Adult Stem Cell science are so mind boggling in terms of healing physical damage and the elimination of disease that the scientific community must focus on what works best, with the least amount of risk and the greatest scope of application," said Drapeau.

Media Contact: Maggie Jessup 360.521.0437 or maggie@platformstrategy.com

Christian Drapeau: America's best known advocate for Adult Stem Cell research and the medical applications of Adult Stem Cells. His theory that Adult Stem Cells are nothing less than the body's natural healing system has profound implications for every area of modern medicine. He holds a Masters degree in neurophysiology from the Department of Neurology and Neurosurgery at Montreal's McGill University. http://www.christiandrapeau.com


'/>"/>
SOURCE Christian Drapeau
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
3. CryoCor Receives FDA Approval for Right Atrial Flutter
4. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
5. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
6. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
9. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
10. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
11. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):